References
- Al-Atram A.A.: A review of the bidirectional relationship between psychiatric disorders and diabetes mellitus. Neurosciences, 2018; 23: 91–96
- Al-Janabi I., Arranz M.J., Blakemore A.I., Saiz P.A., Susce M.T., Glaser P.E., Clark D., de Leon J.: Association study of serotonergic gene variants with antipsychotic-induced adverse reactions. Psychiatr. Genet., 2009; 19: 305–311
- American Diabetes Association: 2. Classification and diagnosis of diabetes: Standards of medical care in diabetes - 2020. Diabetes Care, 2020; 43: S14–S31
- Aprahamian I., Santos F.S., dos Santos B., Talib L., Diniz B.S., Radanovic M., Gattaz W.F., Forlenza O.V.: Long-term, low-dose lithium treatment does not impair renal function in the elderly: A 2-year randomized, placebo-controlled trial followed by single-blind extension. J. Clin. Psychiatry, 2014; 75: e672–e678
- Best L., Yates A.P., Reynolds G.P.: Actions of antipsychotic drugs on pancreatic β-cell function: Contrasting effects of clozapine and haloperidol. J. Psychopharmacol., 2005; 19: 597–601
- Blonde L., Kan H.J., Gutterman E.M., L’Italien G.J., Kim M.S., Hanssens L., McQuade R.D.: Predicted risk of diabetes and coronary heart disease in patients with schizophrenia: Aripiprazole versus standard of care. J. Clin. Psychiatry, 2008; 69: 741–748
- Burcu M., Zito J.M., Safer D.J., Magder L.S., dosReis S., Shaya F.T., Rosenthal G.L.: Concomitant use of atypical antipsychotics with other psychotropic medication classes and the risk of type 2 diabetes mellitus. J. Am. Acad. Child Adolesc. Psychiatry, 2017; 56: 642–651
- Burghardt K.J., Seyoum B., Mallisho A., Burghardt P.R., Kowluru R.A., Yi Z.: Atypical antipsychotics, insulin resistance and weight; a meta-analysis of healthy volunteer studies. Prog. Neuropsychopharmacol. Biol. Psychiatry, 2018; 83: 55–63
- Chebane L., Tavassoli N., Bagheri H., Montastruc J.L., Centres Régionaux de Pharmacovigilance Français: Drug-induced hyperglycemia: A study in the French pharmacovigilance database. Therapie, 2010; 65: 447–458
- Chen J., Huang X.F., Shao R., Chen C., Deng C.: Molecular mechanisms of antipsychotic drug-induced diabetes. Front. Neurosci., 2017; 11: 643
- Clark D., Skrobot O.A., Adebiyi I., Susce M.T., de Leon J., Blakemore A.F., Arranz M.J.: Apolipoprotein-E gene variants associated with cardiovascular risk factors in antipsychotic recipients. Eur. Psychiatry, 2009; 24: 456–463
- Das-Munshi J., Ashworth M., Dewey M.E., Gaughran F., Hull S., Morgan C., Nazroo J., Petersen I., Schofield P., Stewart R., Thornicroft G., Prince M.J.: Type 2 diabetes mellitus in people with severe mental illness: Inequalities by ethnicity and age. Cross-sectional analysis of 588 408 records from the UK. Diabet. Med., 2017; 34: 916–924
- De Hert M., Mittoux A., He Y., Peuskens J.: Metabolic parameters in the short- and long-term treatment of schizophrenia with sertindole or risperidone. Eur. Arch. Psychiatry Clin. Neurosci., 2011; 261: 231–239
- Erickson S.C., Le L., Zakharyan A., Stockl K.M., Harada A.S., Borson S., Ramsey S.D., Curtis B.: New-onset treatment-dependent diabetes mellitus and hyperlipidemia associated with atypical antipsychotic use in older adults without schizophrenia or bipolar disorder. J. Am. Geriatr. Soc., 2012; 60: 474–479
- Fathallah N., Slim R., Larif S., Hmouda H., Ben Salem C.: Drug-induced hyperglycaemia and diabetes. Drug Saf., 2015; 38: 1153–1168
- Feng S., Melkersson K.: Metabolic parameters and long-term antipsychotic treatment: A comparison between patients treated with clozapine or olanzapine. Neuro. Endocrinol. Lett., 2012; 33: 493–498
- Findling R.L., Pathak S., Earley W.R., Liu S., DelBello M.P.: Efficacy and safety of extended-release quetiapine fumarate in youth with bipolar depression: An 8 week, double-blind, placebo-controlled trial. J. Child Adolesc. Psychopharmacol., 2014; 24: 325–335
- Foley D., Mackinnon A., Morgan V.A., Watts G.F., Castle D.J., Waterreus A., Galletly C.A.: Effect of age, family history of diabetes and antipsychotic drug treatment on risk of diabetes in people with psychosis: A population-based cross-sectional study. Lancet Psychiatry, 2015; 2: 1092–1098
- Foley D.L., Mackinnon A., Morgan V.A., Watts G.F., Castle D.J., Waterreus A., Galletly C.A.: Awareness of pre-diabetes or diabetes and associated factors in people with psychosis. Schizophr. Bull., 2016; 42: 1280–1289
- Haleem D.J., Sheikh S., Fawad A., Haleem M.A.: Fasting leptin and glucose in normal weight, over weight and obese men and women diabetes patients with and without clinical depression. Metab. Brain Dis., 2017; 32: 757–764
- Hardy T.A., Henry R.R., Forrester T.D., Kryzhanovskaya L.A., Campbell G.M., Marks D.M., Mudaliar S.: Impact of olanzapine or risperidone treatment on insulin sensitivity in schizophrenia or schizoaffective disorder. Diabetes Obes. Metab., 2011; 13: 726–735
- Henderson D.C., Cagliero E., Gray C., Nasrallah R.A., Hayden D.L., Schoenfeld D.A., Goff D.C.: Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: A five-year naturalistic study. Am. J. Psychiatry, 2000; 157: 975–981
- Hermida O.G., Fontela T., Ghiglione M., Uttenthal L.O.: Effect of lithium on plasma glucose, insulin and glucagon in normal and streptozotocin-diabetic rats: Role of glucagon in the hyperglycaemic response. Br. J. Pharmacol., 1994; 111: 861–865
- Holt R.I., Mitchell A.J.: Diabetes mellitus and severe mental illness: Mechanisms and clinical implications. Nat. Rev. Endocrinol., 2015; 11: 79–89
- Jain V., Patel R.K., Kapadia Z., Galiveeti S., Banerji M., Hope L.: Drugs and hyperglycemia: A practical guide. Maturitas, 2017; 104: 80–83
- Kharroubi A.T., Darwish H.M.: Diabetes mellitus: The epidemic of the century. World J. Diabetes, 2015; 6: 850–867
- Kopf D., Gilles M., Paslakis G., Medlin F., Lederbogen F., Lehnert H., Deuschle M.: Insulin secretion and sensitivity after single-dose amisulpride, olanzapine or placebo in young male subjects: Double blind, cross-over glucose clamp study. Pharmacopsychiatry, 2012; 45: 223–228
- Létourneau G., Abdel-Baki A., Dubreucq S., Mahone M., Granger B.: Hyperosmolar hyperglycemic state associated with ziprasidone treatment: A case report. J. Clin. Psychopharmacol., 2011; 31: 671–673
- Lee H., Song D.H., Kwon J.W., Han E., Chang M.J., Kang H.Y.: Assessing the risk of type 2 diabetes mellitus among children and adolescents with psychiatric disorders treated with atypical antipsychotics: A population-based nested case-control study. Eur. Child Adolesc. Psychiatry, 2018; 27: 1321–1334
- Lieberman J.A., First M.B.: Psychotic disorders. N. Engl. J. Med., 2018; 379: 270–280
- Mackin P., Bishop D., Watkinson H.M., Ferrier I.N.: A prospective study of glycaemic status in anti-psychotic-treated patients. J. Psychopharmacol., 2008; 22: 563–566
- Mamakou V., Hackinger S., Zengini E., Tsompanaki E., Marouli E., Serfatinidis I., Prins B., Karabela A., Glezou E., Southam L., Rayner N.W., Kuchenbaecker K., Lamnissou K., Kontaxakis V., Dedoussis G., et al.: Combination therapy as a potential risk factor for the development of type 2 diabetes in patients with schizophrenia: The GOMAP study. BMC Psychiatry, 2018; 18: 249
- McDonnell D.P., Kryzhanovskaya L.A., Zhao F., Detke H.C., Feldman P.D.: Comparison of metabolic changes in patients with schizophrenia during randomized treatment with intramuscular olanzapine long-acting injection versus oral olanzapine. Hum. Psychopharmacol., 2011; 26: 422–433
- Melkersson K.I., Scordo M.G., Gunes A., Dahl M.L.: Impact of CYP1A2 and CYP2D6 polymorphisms on drug metabolism and on insulin and lipid elevations and insulin resistance in clozapine-treated patients. J. Clin. Psychiatry, 2007; 68: 697–704
- Moreno-Küstner B., Martín C., Pastor L.: Prevalence of psychotic disorders and its association with methodological issues. A systematic review and meta-analyses. PLoS One, 2018;13: e0195687
- Nuevo R., Chatterji S., Fraguas D., Verdes E., Naidoo N., Arango C., Ayuso-Mateos J.L.: Increased risk of diabetes mellitus among persons with psychotic symptoms: Results from the WHO World Health Survey. J. Clin. Psychiatry, 2011; 72: 1592–1599
- Pisano S., Coppola G., Catone G., Carotenuto M., Iuliano R., D’Espovito V., Cabaro S., Miraglia Del Giudice E., Bravaccio C., Formisano P.: Differences in metabolic factors between antipsychotic-induced weight gain and non-pharmacological obesity in youths. Clin. Drug Invest., 2018; 38: 457–462
- Ragguett R.M., Hahn M., Messina G., Chieffi S., Monda M., De Luca V.: Association between antipsychotic treatment and leptin levels across multiple psychiatric populations: An updated meta-analysis. Hum. Psychopharmacol., 2017; 32: e2631
- Saeedi P., Petersohn I., Salpea P., Malanda B., Karuranga S., Unwin N., Colagiuri S., Guariguata L., Motala A.A., Ogurtsova K., Shaw J.E., Bright D., Williams R., IDF Diabetes Atlas Committee: Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9th edition. Diabetes Res Clin Pract., 2019; 157: 107843
- Salvi V., Grua I., Cerveri G., Mencacci C., Barone-Adesi F.: The risk of new-onset diabetes in antidepressant users - A systematic review and meta-analysis. PLoS One, 2017; 12: e0182088
- Siafis S., Papazisis G.: Detecting a potential safety signal of anti-depressants and type 2 diabetes: A pharmacovigilance-pharmacodynamic study. Br. J. Clin. Pharmacol., 2018; 84: 2405–2414
- Srisawasdi P., Vanwong N., Hongkaew Y., Puangpetch A., Vanavanan S., Intachak B., Ngamsamut N., Limsila P., Sukasem C., Kroll M.H.: Impact of risperidone on leptin and insulin in children and adolescents with autistic spectrum disorders. Clin. Biochem., 2017; 50: 678–685
- Stroup T.S., Byerly M.J., Nasrallah H.A., Ray N., Khan A.Y., Lamberti J.S., Glick I.D., Steinbook R.M., McEvoy J.P., Hamer R.M.: Effects of switching from olanzapine, quetiapine, and risperidone to aripiprazole on 10-year coronary heart disease risk and metabolic syndrome status: Results from a randomized controlled trial. Schizoph. Res., 2013; 146: 190–195
- Sylvia L.G., Shelton R.C., Kemp D.E., Bernstein E.E., Friedman E.S., Brody B.D., McElroy S.L., Singh V., Tohen M., Bowden C.L., Ketter T.A., Deckersbach T., Thase M.E., Reilly-Harrington N.A., Nierenberg A.A., et al.: Medical burden in bipolar disorder: Findings from the Clinical and Health Outcomes Initiative in Comparative Effectiveness for Bipolar Disorder study (Bipolar CHOICE). Bipolar Disord., 2015; 17: 212–223
- Taylor D., Young C., Mohamed R., Paton C., Walwyn R.: Undiag-nosed impaired fasting glucose and diabetes mellitus amongst in-patients receiving antipsychotic drugs. J. Psychopharmacol., 2005; 19: 182–186
- Teff K.L., Rickels M.R., Grudziak J., Fuller C., Nguyen H.L., Rickels K.: Antipsychotic-induced insulin resistance and postprandial hormonal dysregulation independent of weight gain or psychiatric disease. Diabetes, 2013; 62: 3232–3240
- Vancampfort D., Mitchell A.J., De Hert M., Sienaert P., Probst M., Buys R., Stubbs B.: Type 2 diabetes in patients with major depressive disorder: A meta-analysis of prevalence estimates and predictors. Depress. Anxiety, 2015; 32: 763–773
- van Keulen K., Knol W., Schrijver E.J.M., van Marum R.J., van Strien A.M., Nanayakkara P.W.B.: Prophylactic use of haloperidol and changes in glucose levels in hospitalized older patients. J. Clin. Psychopharmacol., 2018; 38: 51–54
- Ward M., Druss B.: The epidemiology of diabetes in psychotic disorders. Lancet Psychiatry, 2015; 2: 431–451
- Weston-Green K., Huang X.F., Deng C.: Second generation antipsychotic-induced type 2 diabetes: A role for the muscarinic M3 receptor. CNS Drugs, 2013; 27: 1069–1080
- Zhou X., Ren L., Yu Z., Huang X., Li Y., Wang C.: The antipsychotics sulpiride induces fatty liver in rats via phosphorylation of insulin receptor substrate-1 at serine 307-mediated adipose tissue insulin resistance. Toxicol. Appl. Pharmacol., 2018; 345: 66–74